scholarly journals Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer

2020 ◽  
Vol 8 (2) ◽  
pp. e000609
Author(s):  
Yungang Wang ◽  
Yanxia Ding ◽  
Yijun Deng ◽  
Yu Zheng ◽  
Shengjun Wang
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Regulatory Network ◽  
Suppressor Cells ◽  
Therapeutic Strategies ◽  
Heterogeneous Population ◽  
Myeloid Derived Suppressor Cells ◽  
Immature Myeloid Cells ◽  
Inflammatory Bowel

Colitis-associated cancer (CAC) is a specific type of colorectal cancer that develops from inflammatory bowel disease (IBD). Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are essential for the pathological processes of inflammation and cancer. Accumulating evidence indicates that MDSCs play different but vital roles during IBD and CAC development and impede CAC immunotherapy. New insights into the regulatory network of MDSCs in the CAC pathogenesis are opening new avenues for developing strategies to enhance the effectiveness of CAC treatment. In this review, we explore the role of MDSCs in chronic inflammation, dysplasia and CAC and summarize the potential CAC therapeutic strategies based on MDSC blockade.

Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway

2008 ◽  
Vol 135 (3) ◽  
pp. 871-881.e5 ◽  
Author(s):  
Lydia A. Haile ◽  
Reinhard von Wasielewski ◽  
Jaba Gamrekelashvili ◽  
Christine Krüger ◽  
Oliver Bachmann ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Inflammatory Bowel

N04 Knowledge, attitude and perception of inflammatory bowel disease patients towards colorectal cancer risk, its management and the role of healthcare providers: a cross-sectional study in the UK

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S659-S659
Author(s):  
F Khan ◽  
W Czuber-Dochan ◽  
C Norton
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Risk Management ◽  
Cancer Risk ◽  
Bowel Disease ◽  
Initiation Time ◽  
Cross Sectional ◽  
Early Cancer Diagnosis ◽  
Inflammatory Bowel

Abstract Background Inflammatory bowel disease (IBD) increases the risk of colorectal cancer (CRC) and requires specialised cancer risk management. Although literature exists on general disease-related knowledge in IBD patients, limited studies have assessed IBD patients’ knowledge of CRC risk and its management. Consequently, patient perception of the role of a healthcare provider (HCP) in patient education of CRC risk and their attitude towards recommended risk management has not been assessed in UK IBD patients. Methods We conducted a cross-sectional online survey with IBD patients recruited via charity sources from April-July 2019. Adult patients (>18 years) with a confirmed diagnosis of IBD for 2 years and adequate command of English language were included. A self-designed and piloted questionnaire with open and closed-ended questions was used. Closed-ended data were analysed using descriptive statistics and open-ended responses were analysed using content analysis. Fischer’s exact test and bivariate logistic regression were used to test for association between knowledge and patient demographics. Results 92 participants, including 52.5% CD and 67.5% females, responded. 88% knew that IBD increases CRC risk. The mean fear of CRC risk (0–10 visual analogue scale) was 6.37 (SD ± 2.8). One-fifth were aware of colonoscopy as the best screening tool; 88% were unaware of screening initiation time. 90% would agree to their doctor’s recommendation of colonoscopy to ensure early cancer diagnosis and treatment. For dysplasia with 10% risk of CRC, 46.7% would not agree to colectomy mainly due to 10% risk of CRC not being high enough to undergo surgery. Forty-eight per cent of participants said that they never had a discussion about increased CRC risk in IBD with their doctor. Almost two-thirds were not informed about the role of screening/surveillance in cancer. Two-thirds were satisfied with the information provided by their HCP. Overall, patients desired more information about their individualised cancer risk and services available for managing the increased risk. Conclusion IBD patients are well informed about IBD-associated CRC risk, feared this risk greatly but were poorly aware of screening initiation time. HCP’s role in cancer knowledge dissemination was sub-optimal and patients desired more knowledge. We need deeper understanding of patients’ educational needs related to CRC.

Inflammatory bowel disease and colonic disorders

2021 ◽  
pp. 150-208
Author(s):  
Thomas Marjot
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Core Curriculum ◽  
Therapeutic Drug ◽  
Biologic Therapies ◽  
Inflammatory Bowel ◽  
Prevention Of Cancer ◽  
Curriculum Topics

This chapter covers core curriculum topics relating to inflammatory bowel disease (IBD) and colonic disorders. A diagnostic approach to IBD is covered including the role of imaging, endoscopy, histopathology and clinical features. Pathophysiology and epidemiology of IBD is detailed. Management of Ulcerative colitis and Crohn’s disease includes assessment of disease severity, imaging modalities and therapeutic management. Particular focus is given to therapeutic drug monitoring and indications for biologic therapies. Surgical management of IBD is broadly covered including indications, timing and approach. Coverage is also given to the diagnosis and management of extra-intestinal manifestations of IBD, IBD in special situations (pregnancy, elderly, transition) and the prevention of cancer in IBD. Colorectal cancer and benign conditions including constipation, functional gut disorders and other colitides are also featured.

scholarly journals Myeloid-Derived Suppressor Cells in Sepsis

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Dengming Lai ◽  
Chaojin Qin ◽  
Qiang Shu
Keyword(s):  
Secondary Infection ◽  
Suppressor Cells ◽  
Antimicrobial Activities ◽  
Therapeutic Benefit ◽  
Myeloid Derived Suppressor Cells ◽  
Innate Immune Responses ◽  
Suspected Infection ◽  
Adaptive Immune ◽  
Immature Myeloid Cells

Sepsis is a systemic, deleterious host response to widespread infection. Patients with sepsis will have documented or suspected infection which can progress to a state of septic shock or acute organ dysfunction. Since sepsis is responsible for nearly 3 million cases per year in China and severe sepsis is a common, expensive fatal condition in America, developing new therapies becomes a significant and worthwhile challenge. Clinical research has shown that sepsis-associated immunosuppression plays a central role in patient mortality, and targeted immune-enhancing therapy may be an effective treatment approach in these patients. As part of the inflammatory response during sepsis, there are elevations in the number of myeloid-derived suppressor cells (MDSCs). MDSCs are a heterogeneous population of immature myeloid cells that possess immunosuppressive activities via suppressing T-cell proliferation and activation. The role of MDSCs in sepsis remains uncertain. Some believe activated MDSCs are beneficial to the sepsis host by increasing innate immune responses and antimicrobial activities, while others think expansion of MDSCs leads to adaptive immune suppression and secondary infection. Herein, we discuss the complex role of MDSCs in immune regulation during sepsis, as well as the potential to target these cells for therapeutic benefit.

scholarly journals Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence

2019 ◽  
Vol 65 (1) ◽  
pp. 111-118
Author(s):  
Kristin E. Burke ◽  
Jennifer Nayor ◽  
Emily J. Campbell ◽  
Ashwin N. Ananthakrishnan ◽  
Hamed Khalili ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Inflammatory Bowel Disease ◽  
Guideline Adherence ◽  
Bowel Disease ◽  
Inflammatory Bowel ◽  
Interval Colorectal Cancer

Abstract 543: Regulation of Atherosclerosis by Myeloid-Derived Suppressor Cells

2014 ◽  
Vol 34 (suppl_1) ◽  
Author(s):  
Amanda C Foks ◽  
Gijs H van Puijvelde ◽  
Vanessa Frodermann ◽  
Thomas van der Heiden ◽  
Ilze Bot ◽  
...  
Keyword(s):  
Immune Responses ◽  
Magnetic Beads ◽  
Immune Therapy ◽  
Atherosclerotic Lesion ◽  
Suppressor Cells ◽  
Lymphoid Tissues ◽  
Dependent Manner ◽  
Myeloid Derived Suppressor Cells ◽  
Immature Myeloid Cells

Objective: Restoration of immune homeostasis in atherosclerosis represents the ultimate goal of an immune-based therapy. Myeloid-derived suppressor cells (MDSCs) are a population of immature myeloid cells that potently suppress immune responses in various pathological settings, via multiple mechanisms, including inhibition of T cell responses. They express the myeloid markers CD11b and Gr-1 and can accumulate in various lymphoid and non-lymphoid tissues. In the present study, we determined the role of MDSCs in atherosclerosis by an adoptive transfer of CD11b + Gr-1 + cells into LDLr -/- mice fed a Western-type diet. Methods and Results: We isolated CD11b + Gr-1 + cells from the bone marrow of LDLr -/- mice fed a Western-type diet for 2 weeks with magnetic beads and found that they strongly suppressed αCD3/CD28-induced splenocyte proliferation in an IFN-γ and iNOS-dependent manner. Subsequently, we adoptively transferred MDSCs into LDLr -/- mice fed a Western-type diet for 6 weeks, which resulted in a 35% reduction in atherosclerotic lesion formation in the aortic root. MDSC treatment reduced splenic Th1 and Th17 cells with 50% and diminished B cells, in particular circulating B2 cells, and concomitantly impaired their proliferative capacity. Conclusions: Our data prove that MDSCs could represent a novel cell-based immune-therapy to dampen pro-atherogenic immune responses and thereby reduce atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document